Expression of CD44, EGFR, p16, and their mutual combinations in
patients with head and neck cancer: Impact on outcomes of
intensity-modulated radiation therapy

J 2019

Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy

SLÁVIK, Marek, Tetiana SHATOKHINA, Jiří ŠÁNA, Parwez AHMAD, Tomáš KAZDA et. al.

Základní údaje

Originální název

Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy

Autoři

SLÁVIK, Marek (703 Slovensko, domácí), Tetiana SHATOKHINA (804 Ukrajina, domácí), Jiří ŠÁNA (203 Česká republika, domácí), Parwez AHMAD (356 Indie, domácí), Tomáš KAZDA (203 Česká republika, domácí), Iveta SELINGEROVÁ (203 Česká republika, domácí), Markéta HERMANOVÁ (203 Česká republika, domácí), Renata ČERVENÁ (203 Česká republika, domácí), Tomáš NOVOTNÝ (203 Česká republika), Petr BURKOŇ (203 Česká republika, domácí), Pavel SMILEK (203 Česká republika, domácí), Zuzana HORÁKOVÁ (203 Česká republika, domácí), Pavel ŠLAMPA (203 Česká republika, garant, domácí) a Ondřej SLABÝ (203 Česká republika, domácí)

Vydání

Head and Neck, Hoboken, Wiley, 2019, 1043-3074

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30206 Otorhinolaryngology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.538

Kód RIV

RIV/00216224:14110/19:00108450

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/hed.25533

UT WoS

000461866800016

Klíčová slova anglicky

CD44; EGFR; immunohistochemistry; intensity-modulated radiotherapy; P16

Štítky

14110112, 14110126, 14110812, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 3. 2020 22:19, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Background Progress in radiation treatment of head and neck squamous cell carcinoma (HNSCC) deserves the studies focused on molecular predictors that would help to enhance individually tailored treatment. Methods p16/epidermal growth factor receptor (EGFR)/cluster of differentiation-44 (CD44) was immunohistochemically analyzed in 165 HNSCC patients. Results In the entire group and the p16 negative cohort, better 3-year overall survival and locoregional control correlated with p16 positivity, CD44, and EGFR negativity were observed. Combined analysis revealed the worst results in the CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ groups and in the EGFR+/CD44+ within p16 negative cohort. Multivariate analysis found tumor stage, Karnofsky index, p16, and CD44 as prognostic factors of overall survival and clinical stage, and p16 as a prognostic factor for locoregional control. Clinical stage and Karnofsky index affected overall survival and tumor stage. EGFR affected locoregional control in the p16 negative subgroup. Conclusion Our study confirmed the negative effect of CD44 and EGFR and the positive effect of p16 on radiotherapy results.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

NV15-31627A, projekt VaV

Název: Možnosti molekulárně řízené radikální radioterapie nebo radiochemoterapie dle profilu mikroRNA u pacientů se spinocelulárními karcinomy hlavy a krku.

Citovat

SLÁVIK, Marek, Tetiana SHATOKHINA, Jiří ŠÁNA, Parwez AHMAD, Tomáš KAZDA, Iveta SELINGEROVÁ, Markéta HERMANOVÁ, Renata ČERVENÁ, Tomáš NOVOTNÝ, Petr BURKOŇ, Pavel SMILEK, Zuzana HORÁKOVÁ, Pavel ŠLAMPA a Ondřej SLABÝ. Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy. Head and Neck. Hoboken: Wiley, 2019, roč. 41, č. 4, s. 940-949. ISSN 1043-3074. Dostupné z: https://dx.doi.org/10.1002/hed.25533.

@article{1497636,
   author = {Slávik, Marek and Shatokhina, Tetiana and Šána, Jiří and Ahmad, Parwez and Kazda, Tomáš and Selingerová, Iveta and Hermanová, Markéta and Červená, Renata and Novotný, Tomáš and Burkoň, Petr and Smilek, Pavel and Horáková, Zuzana and Šlampa, Pavel and Slabý, Ondřej},
   article_location = {Hoboken},
   article_number = {4},
   doi = {http://dx.doi.org/10.1002/hed.25533},
   keywords = {CD44; EGFR; immunohistochemistry; intensity-modulated radiotherapy; P16},
   language = {eng},
   issn = {1043-3074},
   journal = {Head and Neck},
   title = {Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy},
   url = {http://dx.doi.org/10.1002/hed.25533},
   volume = {41},
   year = {2019}
}

TY  - JOUR
ID  - 1497636
AU  - Slávik, Marek - Shatokhina, Tetiana - Šána, Jiří - Ahmad, Parwez - Kazda, Tomáš - Selingerová, Iveta - Hermanová, Markéta - Červená, Renata - Novotný, Tomáš - Burkoň, Petr - Smilek, Pavel - Horáková, Zuzana - Šlampa, Pavel - Slabý, Ondřej
PY  - 2019
TI  - Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy
JF  - Head and Neck
VL  - 41
IS  - 4
SP  - 940-949
EP  - 940-949
PB  - Wiley
SN  - 10433074
KW  - CD44
KW  - EGFR
KW  - immunohistochemistry
KW  - intensity-modulated radiotherapy
KW  - P16
UR  - http://dx.doi.org/10.1002/hed.25533
L2  - http://dx.doi.org/10.1002/hed.25533
N2  - Background Progress in radiation treatment of head and neck squamous cell carcinoma (HNSCC) deserves the studies focused on molecular predictors that would help to enhance individually tailored treatment. Methods p16/epidermal growth factor receptor (EGFR)/cluster of differentiation-44 (CD44) was immunohistochemically analyzed in 165 HNSCC patients. Results In the entire group and the p16 negative cohort, better 3-year overall survival and locoregional control correlated with p16 positivity, CD44, and EGFR negativity were observed. Combined analysis revealed the worst results in the CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ groups and in the EGFR+/CD44+ within p16 negative cohort. Multivariate analysis found tumor stage, Karnofsky index, p16, and CD44 as prognostic factors of overall survival and clinical stage, and p16 as a prognostic factor for locoregional control. Clinical stage and Karnofsky index affected overall survival and tumor stage. EGFR affected locoregional control in the p16 negative subgroup. Conclusion Our study confirmed the negative effect of CD44 and EGFR and the positive effect of p16 on radiotherapy results.
ER  -

SLÁVIK, Marek, Tetiana SHATOKHINA, Jiří ŠÁNA, Parwez AHMAD, Tomáš KAZDA, Iveta SELINGEROVÁ, Markéta HERMANOVÁ, Renata ČERVENÁ, Tomáš NOVOTNÝ, Petr BURKOŇ, Pavel SMILEK, Zuzana HORÁKOVÁ, Pavel ŠLAMPA a Ondřej SLABÝ. Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy. \textit{Head and Neck}. Hoboken: Wiley, 2019, roč.~41, č.~4, s.~940-949. ISSN~1043-3074. Dostupné z: https://dx.doi.org/10.1002/hed.25533.

Podrobný výpis o publikaci